Bristol-Myers Squibb Co. and Clovis Oncology Inc. formed a clinical collaboration to evaluate the combination of BMS’s Opdivo and Clovis Oncology’s poly (ADP-ribose) polymerase inhibitor Rubraca in pivotal phase III clinical trials in:
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
